Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
This study has been completed.
First Received: October 18, 1999   Last Updated: June 23, 2005   History of Changes
Sponsors and Collaborators: National Center for Research Resources (NCRR)
University of California, Los Angeles
Information provided by: National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier: NCT00004323
  Purpose

OBJECTIVES: I. Evaluate the efficacy of related, HLA-identical bone marrow transplantation following cyclophosphamide (CTX) and antithymocyte globulin in patients with aplastic anemia. II. Evaluate the efficacy of related, HLA-nonidentical bone marrow transplantation following CTX and total-body irradiation/total-lymphoid irradiation in patients with aplastic anemia.


Condition Intervention Phase
Aplastic Anemia
Drug: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: cyclosporine
Drug: mesna
Drug: methotrexate
Drug: methylprednisolone
Phase II

MedlinePlus related topics: Anemia Bone Marrow Transplantation
Drug Information available for: Cyclophosphamide Methotrexate Mesna Cyclosporine Cyclosporin Methylprednisolone
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Efficacy Study

Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment: 10
Study Start Date: February 1995
Detailed Description:

PROTOCOL OUTLINE: Patients with HLA-identical donors receive cyclophosphamide/mesna, antithymocyte globulin (ATG), and methylprednisolone (MePRDL), followed by allogeneic marrow transplantation. Patients with HLA-nonidentical (5/6 or 4/6) donors and those with a systemic reaction to ATG receive the same dosage of myeloablative chemotherapy and rescue. In addition, these patients are treated with total-body irradiation, total-lymphoid irradiation, and methotrexate.

All patients received MePRDL and cyclosporine for graft-versus-host prophylaxis.

  Eligibility

Ages Eligible for Study:   up to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Severe aplastic anemia with 2 of the following criteria: Polymorphonuclear neutrophils no more than 0.5 x 10 to the ninth/L Platelets no more than 20 x 10 to the ninth/L Reticulocytes no more than 30 x 10 to the ninth/L Hypocellular bone marrow Related donor aged 6 weeks or more, matching at least 4 of 6 HLA A, B, and DRI loci, as follows: HLA-identical family member for patients aged less than 40 years HLA-nonidentical family member for patients aged less than 55 years failing antithymocyte globulin or other immunosuppressive therapy The following eligible for transplantation as initial therapy: Patients aged less than 40 years with HLA-matched donor Patients aged 40-45 years with HLA-identical donor No neoplastic or preneoplastic evolution --Patient Characteristics-- Age: Under 40 (55 if ATG failure) Hepatic: No severe liver dysfunction Renal: No severe renal dysfunction Cardiovascular: No severe cardiac dysfunction Other: No other organ dysfunction that would compromise survival after transplant No HIV infection

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004323

Locations
United States, California
Center for Health Sciences
Los Angeles, California, United States, 90024-1714
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Study Chair: Mary Carol Territo University of California, Los Angeles
  More Information

No publications provided

Study ID Numbers: 199/11863, UCLA-94020602
Study First Received: October 18, 1999
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00004323     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):
aplastic anemia
hematologic disorders
rare disease

Study placed in the following topic categories:
Anti-Inflammatory Agents
Antimetabolites
Cyclosporine
Immunologic Factors
Methylprednisolone
Aplastic Anemia
Clotrimazole
Hormone Antagonists
Miconazole
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Cyclophosphamide
Hormones
Neuroprotective Agents
Cyclosporins
Antifungal Agents
Anemia, Aplastic
Methotrexate
Alkylating Agents
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Hematologic Diseases
Tioconazole
Rare Diseases
Anemia
Methylprednisolone acetate
Folic Acid Antagonists
Glucocorticoids
Immunosuppressive Agents

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Antimetabolites
Anti-Infective Agents
Antimetabolites, Antineoplastic
Cyclosporine
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Methylprednisolone
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Reproductive Control Agents
Cyclophosphamide
Hormones
Neuroprotective Agents
Cyclosporins
Antifungal Agents
Therapeutic Uses
Abortifacient Agents
Anemia, Aplastic
Methotrexate
Dermatologic Agents
Alkylating Agents
Nucleic Acid Synthesis Inhibitors
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Hematologic Diseases
Gastrointestinal Agents

ClinicalTrials.gov processed this record on May 07, 2009